Choroideremia Treatment Market Size & Share, by Therapy (Topical Carbonic Inhibitor, Dorzolamide, Gene Therapy, Luxturna, Lutein); Route of Administration (Oral, Intravenous, Opthalmic); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drugstores, Online Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5519
  • Published Date: Jan 08, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Choroideremia Treatment Market size is predicted to reach USD 33 Billion by the end of 2036, expanding around 5% CAGR during the forecast period 2024-2036. In the year 2023, the industry size of choroideremia treatment was over USD 9 Billion. The growth of this market can be ascribed to the increasing prevalence of choroideremia all across the globe. 1 in 50,000 to 100,000 people in the United States has choroideremia according to the Centers for Disease Control and Prevention.

Due to the delay in diagnosis and treatment of patients with Choroideremia, COVID-19 is likely to have an important effect on the therapeutic market for Choroideremia. Anyhow, the result will be short-term and post-COVID-19 pandemic, the choroideremia treatment market will show a significant surge owing to an increase in treatment adoption. The growth in the market for the treatment of choroideremia is expected to be driven by a rising incidence of choroideremia.


Choroideremia Treatment Market
Get more information on this report: Request Free Sample PDF


Choroideremia Treatment Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

~5%

Base Year Market Size (2023)

~USD 9 billion

Forecast Year Market Size (2036)

~USD 33 billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Choroideremia Treatment Sector: Growth Drivers and Challenges

Market-Growth-Drivers

Growth Drivers

  • Growing Advancement in Medical Technology - Progress in healthcare technologies is one of the major drivers for the choroideremia treatment market. There have been a lot of developments in the last few years, which led to new treatment options for choroideremia. Not only did these developments increase the number of available therapies, but they also made them more accessible. The effectiveness of the medicines has been enhanced and it is easier for patients to control their symptoms and increase their quality of life.
  • Growing Investment in Research and Development Activities - Increased R&D spending is also a driving factor for the choroideremia treatment market. Pharmaceutical companies are putting a strong emphasis on R&D in the area of the development of new Choroideremia treatments and therapies, as they seek to introduce new medicinal products into the market. This additional investment, which is projected to lead to a new and better treatment shortly, will be an engine of innovation and growth on the market.
  • Favorable Government Policies - Favorable governmental regulations and policies are also driving the market. Globally, governments are becoming more proactive in promoting the creation and accessibility of therapies for uncommon illnesses such as choroideremia. Patients now have greater access to therapies and treatments that can help control their symptoms thanks to this assistance, which has also encouraged innovation and investment in the sector.

Challenges

  • Complex Disease Pathology – Choroideremia is caused by mutations in the CHM gene that affect the production of a protein essential for the proper function of the retina. The complex interplay between genetics, cellular processes, and visual function makes it challenging to develop effective therapies.
  • Side Effects and Safety Issues Associated with the Treatment is Predicted to Hamper the Market Growth in the Upcoming Period.
  • Limited Access to Specialty is Another Factor Posing Limitations on the Market Growth in the Forecast Period.


Choroideremia Treatment Segmentation

Route of Administration (Oral, Intravenous, Opthalmic)

Based on the route of administration, the ophthalmic segment is anticipated to dominate the global choroideremia treatment market by registering a growth rate of 40% by the end of 2036. The growth of this segment can be attributed on account of increasing integration of gene therapy in opthalmic route of administration. Gene therapy is regarded as a promising approach for treating choroideremia and its adoption is anticipated to rise in the upcoming years. This is owing to factors such as enhanced safety and efficacy profiles of gene therapy vectors and increasing clinical trial data supporting its effectiveness. Biogen Inc. initiated a Phase 3 STAR study of timrepigene emparvovec (BIIB111/AAV2-REP1), an investigational gene therapy for the potential treatment of choroideremia.

Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drugstores, Online Pharmacies)

Based on the distribution channel, the hospital pharmacies segment in the choroideremia treatment market is set to hold the highest CAGR of 40% by the end of 2036. Hospital pharmacies often serve as the central distribution point for specialized and high-cost medications such as those targeted for rare diseases like choroideremia. This efficiency in supply chain management could benefit patients by ensuring timely access to treatment. Furthermore, as new choroideremia treatments especially gene therapy approaches reach the market, innovative reimbursement pathways are being explored. Hospital pharmacies are likely to play a crucial role in navigating these play a key role in navigating these reimbursement complexities and facilitating patient access to treatment.

Our in-depth analysis of the global choroideremia treatment market includes the following segments:

Therapy

  • Topical Carbonic Inhibitor
  • Dorzolamide
  •  Gene Therapy
  •  Luxturna
  • Lutein

Administration

  • Oral
  • Intravenous
  • Opthalmic

Distribution Channel

  • Hospital Pharmacies
  •  Retail Pharmacies
  •  Drugstores
  • Online Pharmacies

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Choroideremia Treatment Industry - Regional Synopsis

North American Market Forecast

The choroideremia treatment market in the North American region is set to dominate the market with a share of 35 % during the forecast period. North America is an epicenter of innovation and technology that has helped the region establish itself as a leader in the healthcare industry. The same is true for the North American market, where advancements in research and development are driving the market to reach new heights. One of the key drivers of the choroideremia treatment market in North America is the existence of a strong medical infrastructure. The growth could also be explained by a number of clinical centers that specialize in the diagnosis and treatment of Choroideremia. These centers offer many services, e.g. genetic testing, low visual impairment rehabilitation, and access to experimental medicinal products like gene therapy. For instance, the Choroideremia Research Foundation CRFC is a nongovernmental organization dedicated to funding research on potential treatments and cures for Choroideremia in Canada. These factors are anticipated to boost the market growth of the market in the North American region.

APAC Market Statistics

The choroideremia treatment market in the Asia Pacific region is predicted to grow significantly by the end of 2036. The Asia Pacific region is experiencing rapid economic growth leading to escalating disposable incomes in many countries. This makes patients more willing and able to afford costly choroideremia treatments. Governments in the region are also investing highly in infrastructure, making advanced treatments more accessible to patients. Furthermore, recent advancements in gene therapy and optogenetics hold promise for the development of more effective treatments for choroideremia. Several clinical trials are currently underway in the Asia Pacific region for novel therapies that could boost the market growth in the future.

Research Nester
Choroideremia Treatment Market size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Choroideremia Treatment Landscape

top-features-companies
    • Novartis AG
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis
    • Spark Therapeutics
    • Bluebird Bio Inc.
    • Biogen Inc.
    • Copernicus Therapeutics, Inc.
    • 4D Molecular Therapeutics
    • Wize Pharma Inc.
    • Retina Implant AG
    • Hoffmann-La Roche Ltd
    • Pixium Vision

In-the-news

In The News

  • A Phase 1 clinical trial of Roche's licensed product candidate 4D-110, administered by a single intravitreal injection for choroidemia, will begin, according to 4D Molecular Therapeutics, lead developer of clinical-stage precision. The first patient in the trial was dosed. The AAV gene medicine controlled based on directed evolution. A genetic retinal disease called choroideremia, which causes blindness and is currently incurable, is inherited in an X-linked manner.
  • Kiora Pharmaceuticals has been approved to treat up to six other patients in the ABACUS study KIO301, for which it obtained an investigational new medicinal product approval in Australia. Initially, ABACUS was designed for the purpose of evaluating patients with retinitis pigmentosa. Kiora applied for this approval to evaluate additional patients with late stage RP as well as those with late stage Choroideremia, a rare form of hereditary retinal degeneration, on the basis of encouraging results shared.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5519
  • Published Date: Jan 08, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The growing prevalence of choroideremia and growing advancement in medical technology are some of the major factors anticipated to drive the growth of the choroideremia treatment market.

The market is anticipated to attain a CAGR of ~5% over the forecast period, i.e., 2024-2036.

The major players in the market are of Biogen, Copernicus Therapeutics, Inc., 4D Molecular Therapeutics, Wize Pharma Inc., Retina Implant AG, Hoffmann-La Roche Ltd, and others.

The opthalmic segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in North America is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Choroideremia Treatment Market Report Scope
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying